Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 61

Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Postmenopausal Vaginal Atrophy Therapeutics market. The report identifies the key trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Postmenopausal Vaginal Atrophy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Postmenopausal Vaginal Atrophy Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postmenopausal Vaginal Atrophy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Postmenopausal Vaginal Atrophy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Postmenopausal Vaginal Atrophy Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Postmenopausal Vaginal Atrophy Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Postmenopausal Vaginal Atrophy Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Postmenopausal Vaginal Atrophy Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Postmenopausal Vaginal Atrophy Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Diagnosis
2.6.1 Laboratory Diagnosis Tests
2.7 Treatment and Management Options
2.7.1 Vaginal Cream
2.7.2 Estradiol Ring
2.7.3 Vaginal Tablet
2.8 GlobalData Pipeline Report Guidance
3 Postmenopausal Vaginal Atrophy Therapeutics - Market Characterization
3.1 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Global
3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Global
3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The US
3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The US
3.5 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - France
3.6 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - France
3.7 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Germany
3.8 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Germany
3.9 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Italy
3.10 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Italy
3.11 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Spain
3.12 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Spain
3.13 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The UK
3.14 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The UK
3.15 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Japan
3.16 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Postmenopausal Vaginal Atrophy Therapeutics Market
3.17.1 Drivers for the Postmenopausal Vaginal Atrophy Therapeutics Market
3.17.2 Barriers to the Postmenopausal Vaginal Atrophy Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Postmenopausal Vaginal Atrophy Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Postmenopausal Vaginal Atrophy Therapeutics Market
4.3.1 Vaginal Cream
4.3.2 Estrace
4.3.3 Premarin
4.3.4 Vaginal Ring
4.3.5 Estring
4.3.6 Femring
4.3.7 Vaginal Tablet
4.3.8 Vagifem
4.4 Key Takeaway
5 Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Postmenopausal Vaginal Atrophy Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline
5.3.2 Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline
5.3.3 Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline
5.3.4 Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline
5.3.5 Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase
5.3.6 Technology Trends Analytic Framework
5.4 Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Mechanism of Action
5.5 Postmenopausal Vaginal Atrophy Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Ophena (ospemifene)
5.6.2 Vaginorm (dehydroepiandrosterone)
5.7 Key Takeaway
6 Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Clinical Trials by Overall Sponsors
6.6 Top Companies Participating in Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials
7 Postmenopausal Vaginal Atrophy Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Postmenopausal Vaginal Atrophy Therapeutics - Implications for Future Market Competition
8 Postmenopausal Vaginal Atrophy Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Bionovo, Inc. (Bionovo)
8.2.2 QuatRx Pharmaceutical Company
8.2.3 Shionogi & Co.
8.2.4 EndoCeutics, Inc
8.2.5 Bayer AG
8.2.6 Other Companies in Postmenopausal Vaginal Atrophy Therapeutics Market
9 Postmenopausal Vaginal Atrophy Therapeutics - Appendix
9.1 Market Definitions
9.2 Acronyms
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: Postmenopausal Vaginal Atrophy Prevalence in The US, EU5 and Japan
Table 2: Treatment Options for Postmenopausal Vaginal Atrophy
Table 3: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 4: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 5: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 6: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 7: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011
Table 8: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019
Table 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2010-2019
Table 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 13: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 14: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 15: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 16: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 17: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 18: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 19: Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline, 2011
Table 20: Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline, 2011
Table 21: Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline, 2011
Table 22: Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline, 2011
Table 23: Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase, 2011
Table 24: Postmenopausal Vaginal Atrophy Therapeutics - Most Promising Drugs Under Clinical Development, 2011
Table 25: Postmenopausal Vaginal Atrophy Therapeutics Market - Clinical Trials by Country, 2011
Table 26: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011
Table 27: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011
Table 28: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011
Table 29: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011
Table 30: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 31 Bionovo Inc., Women’s Healthcare Pipeline, 2011
Table 32: QuatRx Pharmaceuticals Company, Women’s Healthcare Pipeline, 2011
Table 33: Shionogi Pharmaceuticals - Women’s Healthcare Pipeline, 2011
Table 34: EndoCeutics - Women’s Healthcare Pipeline, 2011
Table 35 Bayer AG - Women’s Healthcare Pipeline, 2011
Table 36: Postmenopausal Vaginal Atrophy Therapeutics Market - Future Players

1.2 List of Figures
Figure 1: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 2: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 3: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 4: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 5: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 6: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 7: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 8: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 13: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 14: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 15: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 16: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 17: Opportunity and Unmet Need in the Postmenopausal Vaginal Atrophy Therapeutics Market, 2011
Figure 18: Postmenopausal Vaginal Atrophy Therapeutics - Strategic Competitor Assessment, 2011
Figure 19: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Phase of Development, 2011
Figure 20: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework, 2011
Figure 21: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 22: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 23: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Country, 2011
Figure 24: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011
Figure 25: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011
Figure 26: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011
Figure 27: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011
Figure 28: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 29: Postmenopausal Vaginal Atrophy Therapeutics Market - Drivers and Barriers, 2011
Figure 30: Implications for Future Market Competition in the Postmenopausal Vaginal Atrophy Market, 2011
Figure 31: Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Company, 2011
Figure 32: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information on the global postmenopausal vaginal atrophy therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global postmenopausal vaginal atrophy therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global postmenopausal vaginal atrophy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Postmenopausal Vaginal Atrophy Therapeutics Market is Forecast to Witness High Growth until 2019

GlobalData’s analysis indicates that the global postmenopausal vaginal atrophy therapeutics market was worth $1,634.5m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 8.0% during 2006-2011.The market is expected to grow at a CAGR of 8.5% during 2011-2019 to $3,144.3m in 2019. Estrogen Replacement Therapy (ERT) is the mainstay of treatment for postmenopausal vaginal atrophy patients. The currently used treatment options can be divided into four categories: vaginal cream, vaginal tablets, vaginal rings and oral estradiol, all of which are types of ERT. Estrace cream (estradiol) by Warner Chilcott and Premarin cream (conjugated estradiol) by Pfizer are examples of vaginal creams, while Vagifem (estradiol) is a vaginal tablet and is marketed by Novo Nordisk. Femring (estradiol, extended release) by Warner Chilcott and Estring (estradiol acetate, extended release) by Pfizer are types of vaginal ring. Oral estradiol is least preferred treatment option because its usage is associated with adverse events such as deep vein thrombosis, Coronary Heart Disease (CHD), stroke, and invasive breast cancer. Of these treatment options, vaginal cream and vaginal tablets are most widely used. The growth witnessed during 2006-2011 was due to increasing awareness of postmenopausal vaginal atrophy among patients and physicians, which resulted in increased diagnosis and treatment rates. The market is expected to show high growth during the forecast period (2011-2019) due to the expected launch of Phase III FIC pipeline molecules Vaginorm (dehydroepiandrosterone) and Ophena (ospemifene) in the US. They will further improve patient compliance through improved safety and efficacy profiles and therefore drive market growth during the forecast period.

Bionovo, Inc. (Bionovo)
QuatRx Pharmaceutical Company
Shionogi & Co.
EndoCeutics, Inc
Bayer AG

Customers who bought this item also bought

• Global Muscular Atrophy Pipeline Capsule - 2013
• Global Muscular Atrophy Drug Pipeline Capsule - 2012
• Vaginal Atrophy - Pipeline Review, Q4 2010
• Global Muscular Atrophy Drug Pipeline Capsule - 2011
• Transdermal Hormone Replacement. Products, Players, Markets, Forecasts
• Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2012
• Muscle Atrophy - Pipeline Review, H1 2013
• Hormone Replacement Therapy (HRT) - Global Strategic Business Report
• Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2012
• Intranasal Drug Delivery - Global Business Strategic Report